The EPS beat and cash runway extension are modest positives, but the company remains pre-revenue with significant cash burn. Key catalysts are the upcoming ELEVATE-44-201 Cohort 1 open-label data (year-end 2026) and Cohort 2 data (Q1 2027), as well as Vertex's GALILEO interim results in H2 2026. Monitor these readouts for efficacy signals that could drive stock movement.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $4.55entry
- T+1 · 11d ago +7.47%α +7.16% · $4.89
- T+5 · 5d ago +13.63%α +10.34% · $5.17
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Entrada Therapeutics reported Q3 2026 net loss of $39.7M ($0.94 per share), narrower than the $44.1M loss in Q3 2025, on collaboration revenue of $0.9M. The company highlighted progress in its DMD clinical programs with multiple upcoming data readouts through H1 2027, and extended cash runway into Q4 2027 with $193M in cash. The EPS of -$0.94 was a smaller loss than the consensus estimate of -$0.99, representing a beat.
Key Financial Metrics
Key Facts
- Net loss of $39.7M for Q3 2026 vs $44.1M in Q3 2025
- EPS of -$0.94 vs consensus -$0.99 (beat)
- Collaboration revenue of $0.9M vs $1.6M in Q3 2025
- Cash, cash equivalents and marketable securities of $193M as of Sep 30, 2026, down from $295.7M at Dec 31, 2025
- Cash runway extended into Q4 2027
- ELEVATE-44-201 Cohort 1 open-label data expected by year-end 2026
- ELEVATE-44-201 Cohort 2 data expected in Q1 2027
- ELEVATE-45-201 Cohort 1 data reported in October 2026 met primary safety objective
- ELEVATE-45-201 Cohort 2 data expected in H1 2027
- Vertex's GALILEO study interim results expected in H2 2026
Financial Impact
Net loss improved by $4.4M YoY; cash burn of ~$102.7M in 9 months; EPS beat consensus by $0.05
Risk Factors
- Cash burn rate of ~$102.7M over 9 months implies limited runway beyond Q4 2027 without additional financing
- Clinical-stage biotech with no approved products; all programs are investigational
- Dependence on positive clinical data from multiple ongoing studies
- Collaboration revenue declined 44% YoY, reducing non-dilutive funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396221 |
Track record
21 reports on TRDA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +58.22% at T+20 after the May 4, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Viewing Entry $4.55 Now $5.00 +9.89% settles Feb 3
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
- Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
- Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 3/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $7.27 Now $5.00 −31.22% settles Nov 20
- Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers